Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-013641
Filing Date
2025-04-14
Accepted
2025-04-14 09:00:27
Documents
18
Period of Report
2025-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20046104x2_def14a.htm   iXBRL DEF 14A 454293
3 GRAPHIC ny20046104x2_pc01.jpg GRAPHIC 686314
4 GRAPHIC ny20046104x2_pc02.jpg GRAPHIC 461766
5 GRAPHIC ny20046104x2_pvp01.jpg GRAPHIC 115439
6 GRAPHIC ny20046104x2_pvp02.jpg GRAPHIC 114139
7 GRAPHIC ny20046104x2_pvp03.jpg GRAPHIC 90782
  Complete submission text file 0001140361-25-013641.txt   4586796

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA nrxs-20250529.xsd EX-101.SCH 2121
21 EXTRACTED XBRL INSTANCE DOCUMENT ny20046104x2_def14a_htm.xml XML 84874
Mailing Address 11611 N. MERIDIAN ST SUITE 330 CARMEL IN 46032
Business Address 11611 N. MERIDIAN ST SUITE 330 CARMEL IN 46032 (812) 689-0791
Neuraxis, INC (Filer) CIK: 0001933567 (see all company filings)

EIN.: 455079684 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41775 | Film No.: 25834321
SIC: 3845 Electromedical & Electrotherapeutic Apparatus
(CF Office: 03 Life Sciences)